Instalab
logoInstalab

APOE Genotype

Blood or Oral Swab Test
Learn which APOE versions you carry: the strongest common genetic risk factor for late-onset Alzheimer's, with smaller effects on cholesterol and heart risk.
4.8 (3,942 reviews)
Tested by Quest, Genova, Kashi, GB Insights or Fulgent
Physician-reviewed results
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get tested
Self-collect at home with the kit we mail you, or have a phlebotomist draw your blood at home or at a lab
Get results
Explained with clear next steps, no medical jargon

Should you take a APOE test?

This test is most useful if any of these apply to you.

Watching for Alzheimer's in Your Family
This test reads the strongest common genetic risk factor for late-onset Alzheimer's; genetics guidelines advise genetic counseling before testing.
Concerned About Heart Disease
Your genotype nudges LDL cholesterol up or down, though heart care is based on your measured cholesterol and overall risk, not APOE.
Healthy but Building a Prevention Plan
A one-time genetic result that adds background to future cholesterol and brain health results, though it does not change standard prevention advice.
Exploring New Alzheimer's Therapies
For people with early memory symptoms weighing anti-amyloid treatment, APOE testing is recommended beforehand to gauge side-effect risk.

About APOE Genotype

Your APOE genotype (apolipoprotein E genotype) is a single piece of genetic information linked to several common diseases. It tells you which version of a fat-carrying protein your body produces, and that version is linked to your risk of Alzheimer's disease, heart disease, stroke, and even how long you are likely to live. Unlike most blood tests, this one never changes. You are born with your result, and it applies for life.

The three common versions of the APOE protein (called E2, E3, and E4) differ only at two spots in their chain of building blocks (amino acids), yet those differences change how your body handles cholesterol, clears debris from your brain, and responds to inflammation. Knowing which combination you carry gives you a personal risk profile that standard cholesterol tests and cognitive screenings cannot provide.

The Three Versions and What They Mean

Everyone inherits two copies of the APOE gene, one from each parent, creating six possible genotype combinations: E2/E2, E2/E3, E2/E4, E3/E3, E3/E4, and E4/E4. The E3 version is the most common in every population studied (up to about 85% to 90% of APOE copies in Mediterranean populations) and serves as the baseline reference. E4 is the version associated with higher disease risk, while E2 is generally protective. If a report shows only the DNA position that marks E4 (rs429358, where the letter C means E4 and T means no E4), a T/C result means one E4 copy and C/C means two, but such a result cannot tell E3 from E2.

About 75% of the APOE protein circulating in your blood is made by your liver, where it acts as a shuttle for cholesterol and triglycerides. But APOE is also produced in your brain, primarily by support cells called astrocytes, where it distributes cholesterol and fats to neurons. The brain and blood pools of APOE are separate and do not mix across the blood-brain barrier, which is one reason the same gene variant can affect both your heart and your brain through different mechanisms.

Alzheimer's Disease Risk

APOE is the strongest common genetic risk factor for late-onset Alzheimer's disease. In a pooled analysis of 5,930 people with Alzheimer's and 8,607 without it, white people from clinic and autopsy studies who carried one E4 copy (E3/E4) had about 3 times the odds of Alzheimer's of people with the most common genotype, E3/E3, and people with two copies (called E4 homozygotes) had about 15 times the odds, while E2/E3 carriers had about 40% lower odds. Odds ratios like these exaggerate differences in actual risk for a common disease, so the lifetime risks below are a better guide to what the numbers mean for one person.

In the Rotterdam Study, which followed over 12,000 people, combining APOE genotype with a broader genetic risk score made the spread even more striking. E4/E4 carriers in the highest third of that score reached a 63% chance of Alzheimer's by age 85, while people with E2/E2 or E2/E3 in the lowest third had just a 4% chance. That is a 59 percentage point gap, though this test reads only APOE, not the other 23 genetic variants in that risk score.

One detail that often gets lost: APOE E4 raises both the chance of developing Alzheimer's and how early it tends to start. In families with late-onset Alzheimer's, symptoms began at about age 84 on average with no E4 copies and about 68 with two, with one copy in between. In people of European ancestry, a large study of lifetime risk put the chance of Alzheimer's by age 85 at about 23% to 35% with one E4 copy (E3/E4) and about 51% to 68% with two, compared with about 11% to 14% for people in general. Carrying E4 is a risk factor, not a diagnosis.

Ancestry Changes the Math

The strength of the E4/Alzheimer's link varies significantly by population. In a large multi-ancestry analysis, the odds ratio (how many times higher the odds of Alzheimer's were) for E3/E4 carriers compared to E3/E3 was 4.54 in East Asian populations, 3.46 in non-Hispanic White populations, 2.18 in non-Hispanic Black populations, and 1.90 in Hispanic populations. The protective effect of E2 also differs: it significantly reduces risk in White populations but shows no measurable protection in East Asian populations. Risk estimates derived from predominantly White study populations should not be applied directly to people of other backgrounds.

Sex matters too. Among non-Hispanic White individuals between ages 60 and 70, the odds ratio for E3/E4 compared with E3/E3 was about 1.5 times as high in women as in men. This sex difference was also seen in a combined analysis of Black and Hispanic individuals.

Heart Disease and Stroke

APOE E4 raises LDL cholesterol by an average of about 6 mg/dL compared to E3/E3, while E2 lowers it by about 17 mg/dL. These shifts have real cardiovascular consequences. In a 2007 meta-analysis that also included unpublished data, covering 121 studies and nearly 38,000 heart disease cases, E2 carriers had about 20% lower coronary risk than E3/E3, while E4 carriers had only about 6% higher risk, a difference that was not statistically significant. Another meta-analysis of 30 published studies, including nearly 12,000 heart disease cases, found that E4/E4 homozygotes had a 45% increased risk compared to E3/E3, though a 2023 analysis of large population cohorts found a smaller increase of about 11% for ischemic heart disease.

For stroke, the evidence is mixed. A meta-analysis of 55 published studies found E4 carriers were about 37% more likely to have an ischemic stroke (the kind caused by a blood clot), and E4/E4 homozygotes 83% more likely than E3/E3. But a meta-analysis that also included unpublished data found much smaller increases (about 5% with one E4 copy and 12% with two) that were not statistically significant. On the protective side, E2/E3 carriers had a 15% lower risk of ischemic stroke.

The E2 Paradox

E2 is generally the protective version: lower LDL, lower Alzheimer's risk, longer lifespan. But E2/E2 homozygotes (fewer than 1 in 100 people of European ancestry) face a specific and somewhat counterintuitive risk. Because the E2 protein does not bind as well to the receptors that clear leftover fat particles from the blood, E2/E2 carriers can develop a condition called type III hyperlipoproteinemia (a buildup of leftover fat particles in the blood), where these remnant particles accumulate and can drive early atherosclerosis (plaque buildup in the arteries).

The 2023 analysis of large population cohorts mentioned above also found that E2/E2 homozygotes had a 49% higher risk of peripheral arterial disease (reduced blood flow to the legs) compared to E3/E3 carriers. A large UK Biobank analysis also linked E2/E2 homozygosity (carrying two copies of E2) to higher risk of blood clots and arterial aneurysm. Even so, E2/E2 was not linked to a higher risk of death overall in the large survival study described below, and only a minority of E2/E2 carriers (about 15% in one review) develop type III hyperlipoproteinemia, which shows up as high cholesterol and triglycerides on a standard lipid panel.

Longevity and All-Cause Mortality

The E2-CHARGE consortium pooled data from over 38,000 people across six population-based studies, tracking more than 17,000 deaths over an average of nearly 12 years. E4 carriers had a 17% higher risk of dying from any cause compared to E3/E3 carriers, with E4/E4 homozygotes facing a 52% higher risk. E2 carriers, by contrast, had about a 6% lower risk of death.

GenotypeMortality Risk vs. E3/E3Pattern
E2/E2About 11% lower (not statistically significant)Trend toward protection
E2/E3About 6% lower (E2/E2 and E2/E3 combined)Modest protection
E3/E3ReferenceBaseline risk
E3/E4About 17% higher (E3/E4 and E4/E4 combined)Increased risk
E4/E4About 52% higherSubstantially increased risk

Source: E2-CHARGE consortium, Wolters et al. (38,537 participants, six cohorts, mean 11.7-year follow-up).

When researchers censored for dementia (meaning they stopped counting each person's follow-up once that person was diagnosed with dementia), the E4-mortality link weakened considerably, dropping from a 17% to a 7% increase. This suggests that much of the excess mortality associated with E4 is driven by its effect on Alzheimer's disease and dementia, although a pooled 2024 analysis of two other cohorts found that dementia explained the excess mainly in E4/E4 homozygotes, not in people with one E4 copy. Two Copenhagen population studies with over 105,000 participants combined confirmed the link between APOE genotype and risk of death, and the 2024 analysis found that E4 carriers had higher cardiovascular death rates but no higher cancer death rates.

Cancer Associations

A 2025 meta-analysis of 38 studies concluded that APOE genotype is not a major risk factor for cancer: effects were small overall, and no single genotype comparison was statistically significant for all cancers combined. For lung cancer, E4 carriers had a higher risk than non-carriers, but that estimate was imprecise. Colorectal cancer showed a smaller effect, with E4/E3 carriers having about a 7% increased risk. A separate 2020 study of melanoma (skin cancer) found the reverse of the Alzheimer's pattern for outcomes after diagnosis: patients carrying E4 survived longer than those carrying E2.

Genotype Categories

Because APOE genotype is a fixed genetic result (not a number that fluctuates), there are no traditional reference ranges. Instead, results are interpreted by genotype category and the disease-risk profile each one carries.

GenotypePopulation FrequencyRisk Profile
E2/E2About 0.6%Lowest Alzheimer's risk; small chance of a genetic cholesterol and triglyceride disorder (type III hyperlipoproteinemia); higher peripheral artery disease risk
E2/E3About 12%Below-average Alzheimer's and cardiovascular risk; generally favorable
E2/E4About 2.6%One protective and one risk copy: Alzheimer's risk likely above average, as E2 does not fully offset E4; LDL cholesterol slightly below average
E3/E3About 58%Population average risk; the reference genotype
E3/E4About 24%Moderately elevated Alzheimer's risk, especially in women ages 60 to 70; slightly higher LDL cholesterol and heart disease risk
E4/E4About 2.4%Highest Alzheimer's risk (about half to two-thirds by age 85 in a large study); higher LDL cholesterol, modestly higher heart disease risk, and higher all-cause mortality risk

These frequencies come from about 337,000 white British UK Biobank participants and vary by ancestry. The risk profiles summarize average effects across large populations. Your individual risk is shaped by your full genetic background, lifestyle, and other health conditions.

Why Your Result Is Permanent

Unlike most biomarkers covered on this site, your APOE genotype is determined at conception and never changes. Your inherited DNA sequence stays the same at every age, regardless of illness, medication, diet, or anything else (the rare exception for blood and cheek-swab samples is a past donor stem cell transplant). This means you only need to take this test once. A second test would give the same result.

This permanence is actually a strength. Instead of tracking a number that bounces around with meals, hydration, and sleep, you get a single, fixed result that adds background to some of your other tests. If you carry E4 (without E2), your LDL cholesterol tends to run slightly higher on average, your brain's ability to clear amyloid (a sticky protein that builds up in Alzheimer's disease) may be slower, and certain medications carry different risk-benefit calculations. That context applies for the rest of your life.

How APOE Shapes Your Response to Treatment

Knowing your APOE genotype is becoming directly relevant to treatment decisions. For Alzheimer's disease, APOE genotyping is recommended before starting a new class of drugs called anti-amyloid antibodies (such as lecanemab) because E4/E4 homozygotes face a substantially higher risk, and people with one E4 copy a somewhat higher risk, of a side effect called ARIA, which involves brain swelling or small bleeds visible on MRI. In some countries, E4/E4 homozygotes are excluded from treatment entirely.

For cardiovascular treatment, studies of whether APOE genotype changes how much statins lower LDL cholesterol have given inconsistent results, and a meta-analysis of 24 studies found no significant difference between genotypes. Either way, current US guidelines base cholesterol treatment on your measured levels and overall heart risk, not on APOE genotype.

What This Test Cannot Tell You

APOE genotyping identifies genetic susceptibility. It does not diagnose any disease, and it does not tell you whether disease has already started. An E4/E4 carrier with no symptoms may never develop Alzheimer's, and an E3/E3 carrier is not immune. Used alone, APOE genotyping is a poor diagnostic test: in a large study of dementia patients whose diagnosis was confirmed at autopsy, E4 status had a sensitivity of about 65% for Alzheimer's (meaning it missed about a third of cases) and a specificity of about 68%.

If you want to know whether amyloid plaques are currently forming in your brain, you would need a different kind of test entirely: either a spinal fluid analysis measuring amyloid and tau proteins, a blood-based biomarker panel (such as plasma p-tau217), or an amyloid PET brain scan. APOE genotyping tells you about your genetic starting position. These other tests tell you where you are right now.

Frequently Asked Questions

References

62 studies
  1. Verghese PB, Castellano JM, Holtzman DMThe Lancet Neurology2011
  2. Martinez-martinez AB, Torres-perez E, Devanney NNeurobiology of Disease2020

APOE Testing Options

$145
1 biomarker
$465

One buccal swab reads 49 pharmacogenomic genes to show which antidepressants, pain medications, statins, blood thinners, chemotherapies and anesthetics your body clears normally, slowly or too fast.

49 biomarkers
$499

Screens 140+ genes linked to inherited cholesterol disorders and other hidden drivers of heart disease risk.

162 biomarkers
FSA/HSA eligible
No Rx needed
HIPAA compliant